Pyrimethamine

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Chemotherapy, antimalarials.

Half-lifeThis section has been translated automatically.

> 4 days

Pharmacodynamics (Effect)This section has been translated automatically.

Inhibition of dihydrofolate reductase.

Spectrum of actionThis section has been translated automatically.

In combination with sulfones or sulfonamides effective against all human pathogenic Plasmodium spp., as single agent against Toxoplasma gondii.

IndicationThis section has been translated automatically.

In combination preparations for malaria tertiana. Therapy of toxoplasmosis including ocular and congenital manifestations and immunodeficiency.

Limited indicationThis section has been translated automatically.

Pregnancy, folic acid deficiency, liver dysfunction, megaloblastic anemia, renal insufficiency.

Dosage and method of useThis section has been translated automatically.

  • Curative malaria therapy (malaria without complications): Application in combination with sulfadoxin (combination preparation: Fansidar contains 500 mg pyrimethamine and 25 mg sulfadoxin): 1500 mg pyrimethamine/75 mg sulfadoxin p.o. as 1-day therapy. Dose reduction for children and adults < 45 kg bw.
  • Toxoplasmosis (in combination with 4 g sulfadiazin/day p.o.): adults and children > 6 years: 100 mg/day for 3 weeks in combination with folic acid 100 mg/day.
  • Toxoplasmosis encephalitis in AIDS: 100 mg/day in combination with sulfadiazine and folic acid, followed by recurrent prophylaxis at 50 mg/day.

Remember! Before therapy determination of glucose-6-phosphate dehydrogenase.

Undesirable effectsThis section has been translated automatically.

Blood count changes, allergic reactions, headaches, heart rhythm disturbances, gastrointestinal complaints, insomnia, dry mouth, shock.

InteractionsThis section has been translated automatically.

See Table 1.

ContraindicationThis section has been translated automatically.

Severe hematopoiesis, lactation.

PreparationsThis section has been translated automatically.

Daraprim; Fansidar (combination with sulfadoxine)

TablesThis section has been translated automatically.

Significant interactions of pyrimethamine

Dapson

Haematotoxicity ↑

Sulfonamides

Haematotoxicity ↑

Trimethoprim

Haematotoxicity ↑

Zidovudine

Zidovudine toxicity ↑

Cytostatics

Haematotoxicity ↑

Anticoagulants

Enhanced impact

Authors

Last updated on: 29.10.2020